Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the anti-CD33
immunotoxin HuM-195/rGel that can be given to patients with advanced myeloid malignancies.
This treatment will be given to patients whose leukemia has not responded to prior
chemotherapy.